Brought to you by 
Lion Bioscience acquires Trega in stock swap
12 Jan 2001
Executive Summary
In a stock swap, Lion Bioscience will exchange its American depositary shares to acquire all Trega Biosciences (drug discovery technologies) outstanding shares, paying about $1.35 each--a (pr)38% premium to market average--or $35mm.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lion Bioscience acquires Trega in stock swap
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice